Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar

This is a retrospective cohort study using routinely collected programme data

Abstract

Myanmar has a high burden of Human Immunodeficiency Virus (HIV) and second-line antiretroviral treatment (ART) has been available since 2008 in the public health sector. However, there have been no published data about the outcomes of such patients until now.

This study aims to assess the treatment and programmatic outcomes and factors associated with unfavorable outcomes (treatment failure, death and loss to follow-up from care) among people living with HIV (aged ≥ 10 years) receiving protease inhibitor-based second-line ART under the Integrated HIV Care Program in Myanmar between October 2008 and June 2015.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Kyaw NTT, Kumar AM V, Oo MM, Oo HN, Kyaw KWY, Thiha S, Aung TK, Win T, Mon YY, Harries AD. Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar. Global Health Action. 2017;10(1):1290916.

Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar

Published 8 June 2017